Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

CAFC
  • US 10,195,214 B2
  • Filed: 06/19/2017
  • Issued: 02/05/2019
  • Est. Priority Date: 03/01/2017
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating Cushing'"'"'s syndrome in a patient who is taking an original once-daily dose of 1200 mg or 900 mg per day of mifepristone, comprising the steps of:

  • reducing the original once-daily dose to an adjusted once-daily dose of 600 mg mifepristone,administering the adjusted once-daily dose of 600 mg mifepristone and a strong CYP3A inhibitor to the patient,wherein said strong CYP3A inhibitor is selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfmavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranivir, paritaprevir and voriconazole.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×